Skip to main content

Recent Development in Cancer Immunotherapy

Edited by Prof Weijing Sun

Due to recent technological and scientific advancements, the past few years have seen dramatic breakthroughs in the burgeoning field of immunotherapy. These and future advances in immunotherapy have the potential to transform cancer treatment and the lives of patients.

This thematic series, published in the Journal of Hematology & Oncology, covers some of the recent advances in cancer immunotherapy.

As discussed by Prof Weijing Sun in the Editorial, important issues addressed by the authors in this series include: the identification of clinically relevant predictive and prognostic biomarkers to help define subgroups of patients who are most likely to benefit from various immunotherapies; management of immunotherapy-related toxicities and resistance; and future directions and approaches.

Articles published in the collection have already gone through the systematic peer review process of the journal.

  1. Currently, conventional therapies for acute myeloid leukemia (AML) have high failure and relapse rates. Thus, developing new strategies is crucial for improving the treatment of AML. With the clinical success ...

    Authors: Mingxue Fan, Minghao Li, Lipeng Gao, Sicong Geng, Jing Wang, Yiting Wang, Zhiqiang Yan and Lei Yu
    Citation: Journal of Hematology & Oncology 2017 10:151
  2. The advent of new immunotherapeutic agents in clinical practice has revolutionized cancer treatment in the past decade, both in oncology and hematology. The transfer of the immunotherapeutic concepts to the tr...

    Authors: Felix S. Lichtenegger, Christina Krupka, Sascha Haubner, Thomas Köhnke and Marion Subklewe
    Citation: Journal of Hematology & Oncology 2017 10:142
  3. Treatment of cancer patients involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. Traditionally, patients with metastatic disease are treated with combination chemotherapies...

    Authors: Kathan Mehta, Keyur Patel and Rahul A. Parikh
    Citation: Journal of Hematology & Oncology 2017 10:95
  4. Patients with advanced melanoma have a compromised anti-tumor immune response leading to tumor immune tolerance and a tumor microenvironment conducive to disease progression. Immunotherapy that successfully ov...

    Authors: Tala Achkar and Ahmad A. Tarhini
    Citation: Journal of Hematology & Oncology 2017 10:88
  5. The chimeric antigen receptor T (CAR-T) cell therapy is a newly developed adoptive antitumor treatment. Theoretically, CAR-T cells can specifically localize and eliminate tumor cells by interacting with the tu...

    Authors: Shengnan Yu, Anping Li, Qian Liu, Tengfei Li, Xun Yuan, Xinwei Han and Kongming Wu
    Citation: Journal of Hematology & Oncology 2017 10:78